Gallium follicular lymphoma
WebJun 20, 2024 · June 11, 2024—Vienna, Austria—A final analysis of the GALLIUM trial have confirmed the role of obinutuzumab-chemotherapy as a standard-of-care option for advanced, previously untreated follicular lymphoma. Findings were presented at the European Hematology Association Hybrid Congress, which took place here and online … WebMay 25, 2024 · 8025 Background: The prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) response assessment following first-line immunochemotherapy for advanced-stage symptomatic follicular lymphoma (FL) was previously demonstrated for patients (pts) enrolled in the Phase III …
Gallium follicular lymphoma
Did you know?
WebMay 25, 2024 · 8023 Background: Immunochemotherapy is standard of care for patients (pts) with previously untreated advanced stage follicular lymphoma (FL). Four-year … WebJan 31, 2024 · GALLIUM participants were adults with follicular lymphoma requiring treatment. They were randomized to receive standard chemotherapy in combination with 6-8 cycles of either intravenous obinutuzumab at a dose of 1,000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of the remaining cycles or intravenous rituximab at a dose of …
WebApr 4, 2024 · Among patients with an EOI CR by CT in GALLIUM and GOYA, 2.8% and 4.1%, respectively, had a BMB-altered response. These results suggest that postinduction BMB histology has minimal impact on radiographically (CT)-defined responses in both FL and DLBCL patients. WebJan 5, 2024 · Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Durig J, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study ...
WebAug 29, 2024 · Bendamustine and rituximab (BR) has become a preferred regimen for frontline treatment of patients with advanced-stage follicular lymphoma (FL) since randomized trials demonstrated impressive efficacy and a favorable toxicity profile. 1, 2 The outcomes of FL patients that progress early, within 24 months of diagnosis or treatment … WebOct 8, 2024 · Follicular lymphoma is the most common indolent non-Hodgkin lymphoma, and has heterogeneous clinical behaviour. Follicular lymphoma is highly sensitive to initial therapy, but is characterised by recurrent relapses and risk of histological transformation.
WebApr 9, 2024 · A minority of patients with follicular lymphoma (FL) undergo histological transformation (HT). This retrospective analysis of 549 patients from the phase 3 GALLIUM study (NCT01332968) assessed the relationship between maximum standardized uptake value (SUVmax) at baseline on positron emission tomography (PET) and HT risk.
WebA randomized, open-label multicenter trial (GALLIUM) evaluated the safety of GAZYVA as compared to rituximab product in 1385 patients with previously untreated follicular … psd snitchpsd soforthilfeWebSep 16, 2024 · Backgrounds: GALLIUM is a global phase III study that demonstrated significant improvements in progression-free survival (PFS) for obinutuzumab plus chemotherapy (G-chemo) vs. rituximab plus chemotherapy (R-chemo) in previously untreated patients with follicular lymphoma (FL). psd slow/totalWebOct 3, 2024 · Micro-AbstractTo improve patient management, more information is needed on follicular lymphoma (FL) histological transformation (HT) incidence, risk factors and … horse shoeing clippersWebFeb 16, 2024 · Answer: We consider bendamustine and rituximab (BR) as our preferred regimen as first-line therapy for a symptomatic patient with follicular lymphoma. To support our preference, we will first discuss the … horse shoeing equipmentWebApproval was based on a multicenter, open-label, randomized phase 3 trial (GALLIUM) for patients with previously untreated non-Hodgkin lymphoma, including 1202 patients with FL. horse shoeing classesWebOct 11, 2024 · Follicular Lymphoma: The GALLIUM Study. Oct 11, 2024. Alan Skarbnik, MD. Dr. Alan Skarbnik reviews the use of obinutuzumab-based therapies for follicular … horse shoeing file